Catriona Yale, Chief Development Officer at Akero Therapeutics, Inc. (AKRO), sold 40,000 shares at $32.53 ($1.3M) on 2024-10-30, disclosed to the SEC on 2024-11-01.
Scheduled sale ($1.3M) by Chief Development Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $32.53 | 4,515 | $147K | 11.3% |
| 2 | $32.53 | 4,515 | $147K | 11.3% |
| 3 | $32.62 | 15,485 | $505K | 38.7% |
| 4 | $32.62 | 15,485 | $505K | 38.7% |
| Total | $32.60 avg | 40,000 | $1.3M | 100% |
| Filing → |
| AKRO | SELL | 2025-06-20 | $876K | — | Filing → |
| AKRO | SELL | 2025-06-20 | $179K | — | Filing → |
| AKRO | SELL | 2025-06-12 | $151K | — | Filing → |